Berchman Vaz, MD
Rheumatology · Tucson, AZNPI 1265468219
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 81.5% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $4,651 and has fallen 98.7% since, to $59 in 2025.
Across 61 payments — averaging $151.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$8K
- Novartis$279
- Amgen$224
- Lilly USA, LLC$213
- Sanofi$165
- AstraZeneca$136
- plus $690 from 14 others
What the payments were for
- Consulting fees$2,80030%
- Speaking & faculty fees$4,15045%
- Travel & lodging$4775%
- Food & beverage$1,80420%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $7,538 |
| Novartis | 4 | $279 |
| Amgen(2 entities) | 7 | $224 |
| Lilly USA, LLC | 8 | $213 |
| Sanofi | 4 | $165 |
| AstraZeneca | 2 | $136 |
| Radius Health, Inc. | 6 | $123 |
| Genentech USA, Inc. | 1 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $80 |
| GSK | 3 | $61 |
| UCB, Inc. | 1 | $56 |
| Johnson & Johnson | 2 | $51 |
| Organon | 4 | $49 |
| Pacira Therapeutics, Inc. | 2 | $36 |
| AbbVie | 2 | $33 |
| Merck | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Orthogenrx Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,246 in reported general payments places this provider in the 60th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 86 | $732,896 |
| EnbrelEtanercept | 33 | $333,436 |
| Humira(Cf) PenAdalimumab | 44 | $322,354 |
| Orencia ClickjectAbatacept | 38 | $222,997 |
| RinvoqUpadacitinib | 26 | $180,381 |
| Cosentyx Sensoready PenSecukinumab | 24 | $179,709 |
| OrenciaAbatacept/Maltose | 24 | $119,413 |
| Humira(Cf)Adalimumab | 14 | $95,824 |
| OrenciaAbatacept | 14 | $77,918 |
| Actemra ActpenTocilizumab | 12 | $50,413 |
| MethotrexateMethotrexate Sodium | 730 | $11,549 |
| Hydroxychloroquine Sulfate | 469 | $11,066 |
| Leflunomide | 109 | $6,365 |
| Diclofenac Sodium | 40 | $3,711 |
| Colchicine | 68 | $3,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $224 | $333,43633 claims |
| AbbVieRinvoq, Humira(Cf) | $33 | $276,20540 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $7,538 | $197,33138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Tucson
- Michael MaricicTucson$110K
- Augusto PosadasTucson$81K
- Romy CabacunganTucson$26K
- Jeffrey LoomerTucson$21K
- Ulker TokTucson$20K
- Jawad BilalTucson$19K
- Chian KwohTucson$12K
- James EvansTucson$5K
- Shannon HoweTucson$4K
- Albert RedfordTucson$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.